<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611424</url>
  </required_header>
  <id_info>
    <org_study_id>FT003WA-1</org_study_id>
    <nct_id>NCT05611424</nct_id>
  </id_info>
  <brief_title>Gene Therapy for Wet AMD</brief_title>
  <official_title>An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FT-003 in Subjects With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frontera Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Frontera Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      FT-003 is a gene therapy product developed for the treatment of neovascular age-related&#xD;
      macular degeneration (nAMD). Neovascular AMD is the main cause of blindness among elderly&#xD;
      individuals. The available therapies for treating nAMD require life-long intravitreal (IVT)&#xD;
      injections every 4-12 weeks to maintain efficacy. Administration of FT-003 has the potential&#xD;
      to treat nAMD by providing durable expression of therapeutic levels of intraocular protein&#xD;
      and maintaining the vision of patients. FT-003 is designed to reduce the current treatment&#xD;
      burden which often results in undertreatment and vision loss in patients with nAMD receiving&#xD;
      anti-VEGF therapy in clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2023</start_date>
  <completion_date type="Anticipated">December 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Neovascular Age-related Macular Degeneration</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability after FT-003 injection</measure>
    <time_frame>At Week 52</time_frame>
    <description>Incidence and severity of AE (Common Terminology Criteria for Adverse Events 5.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in best-corrected visual acuity (BCVA) of the studied eye from baseline</measure>
    <time_frame>At Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>FT003 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose of FT-003</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT003 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid dose of FT-003</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT003 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of FT-003</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>FT-003</intervention_name>
    <description>Administered via intraocular injection.</description>
    <arm_group_label>FT003 Dose 1</arm_group_label>
    <arm_group_label>FT003 Dose 2</arm_group_label>
    <arm_group_label>FT003 Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects that are willing and able to follow study procedures;&#xD;
&#xD;
          -  Female or male patients ≥45 years old at the time of signing the ICF;&#xD;
&#xD;
          -  Clinically diagnosed with nAMD;&#xD;
&#xD;
          -  Presence of active CNV&#xD;
&#xD;
          -  The best corrected visual acuity (BCVA) of the studied eye is ≤ 53 letters;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Presence of any other intraocular diseases other than nAMD in the studied eye that would&#xD;
        affect the improvement of visual acuity and require treatment during the study for&#xD;
        prevention or treatment of visual loss, as judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peirong Lu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaorong Li, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Eye Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanyi Min</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guangming Wan</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinyan Li</last_name>
    <phone>+86-021-58206061</phone>
    <email>Xinyan.li@fronteratherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Minghui Xue</last_name>
    <phone>+86-021-58206061</phone>
    <email>minghui.xue@fronteratherapeutics.com</email>
  </overall_contact_backup>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>April 24, 2023</last_update_submitted>
  <last_update_submitted_qc>April 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

